321 related articles for article (PubMed ID: 8652525)
21. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
J Biol Chem; 1994 Nov; 269(44):27657-62. PubMed ID: 7961684
[TBL] [Abstract][Full Text] [Related]
22. A model of the reactive form of plasminogen activator inhibitor-1.
Aertgeerts K; De Bondt HL; De Ranter C; Declerck PJ
J Struct Biol; 1994; 113(3):239-45. PubMed ID: 7734247
[TBL] [Abstract][Full Text] [Related]
23. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
[TBL] [Abstract][Full Text] [Related]
24. Analysis of serpin inhibitory function by mutagenesis of ovalbumin and generation of chimeric ovalbumin/PAI-2 fusion proteins.
McCarthy BJ; Worrall DM
J Mol Biol; 1997 Apr; 267(3):561-9. PubMed ID: 9126838
[TBL] [Abstract][Full Text] [Related]
25. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
26. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
[TBL] [Abstract][Full Text] [Related]
27. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition.
Ngo TH; Zhou Y; Stassen JM; Declerck PJ
Thromb Haemost; 2002 Aug; 88(2):288-93. PubMed ID: 12195702
[TBL] [Abstract][Full Text] [Related]
28. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.
Pedersen KE; Einholm AP; Christensen A; Schack L; Wind T; Kenney JM; Andreasen PA
Biochem J; 2003 Jun; 372(Pt 3):747-55. PubMed ID: 12656676
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
[TBL] [Abstract][Full Text] [Related]
31. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
[TBL] [Abstract][Full Text] [Related]
32. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
Thromb Haemost; 2000 Nov; 84(5):871-5. PubMed ID: 11127870
[TBL] [Abstract][Full Text] [Related]
33. Serpin-resistant mutants of human tissue-type plasminogen activator.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF
Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599
[TBL] [Abstract][Full Text] [Related]
34. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism.
Shore JD; Day DE; Francis-Chmura AM; Verhamme I; Kvassman J; Lawrence DA; Ginsburg D
J Biol Chem; 1995 Mar; 270(10):5395-8. PubMed ID: 7890653
[TBL] [Abstract][Full Text] [Related]
35. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
Sun Z; Liu JN
Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
[TBL] [Abstract][Full Text] [Related]
36. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
37. Solvent effects on activity and conformation of plasminogen activator inhibitor-1.
Andreasen PA; Egelund R; Jensen S; Rodenburg KW
Thromb Haemost; 1999 Mar; 81(3):407-14. PubMed ID: 10102470
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity.
Jankun J; Specht Z; Szkudlarek M; Greenfield R; Gaikwad B; Trifonov L; Vaugeois J; Aleem AM; Basrur V; Selman SH; Zavodszky MI; Skrzypczak-Jankun E
Int J Mol Med; 2006 Mar; 17(3):437-47. PubMed ID: 16465390
[TBL] [Abstract][Full Text] [Related]
39. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
[TBL] [Abstract][Full Text] [Related]
40. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
J Pharm Belg; 2000; 55(2):57-8. PubMed ID: 10842928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
